Fallowfield, L, Solis-Trapala, I, Starkings, R, Catt, S and Jenkins, V (2019) Talking About Risk in the Context of GEnomic Tests (TARGET): Development and evaluation of an educational program for clinicians. Breast Cancer Research and Treatment, 177 (3). pp. 641-649. ISSN 1573-7217

[thumbnail of Fallowfield2019_Article_TalkingAboutRiskInTheContextOf.pdf]
Fallowfield2019_Article_TalkingAboutRiskInTheContextOf.pdf - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview


Purpose: Gene expression profiling (GEP) test scores calculate risks of recurrence and likely benefit of adjuvant chemotherapy in ER positive, HER2 negative, early stage breast cancer. As health literacy and numeracy skills in the general population are poor, healthcare professionals (HCPs) require a wide repertoire of communication skills to explain clearly risk of recurrence scores (RSs) and uncertainty. We developed and evaluated an educational program for HCPs discussing GEP test results and adjuvant treatment.

Methods: Eight hour workshops contained elements aimed at improving knowledge, communication skills, and self-awareness; these included:- the science underpinning GEP tests, an interactive risk psychology lecture, exercises and facilitated group
discussions regarding 7 filmed scenarios involving discussions about high, intermediate and low RSs. Attendees were recorded explaining RSs with patient simulators pre and post workshop. Researchers blinded to time-point, analysed recordings using a study specific scoring system. Primary objective outcomes were improvements post workshop in HCPs’ competence and confidence when communicating 17 pre-specified key information areas. We estimated odds ratios (OR) using conditional logistic regression to compare pre and post workshop scores.

Results: 65 HCPs attended. Objective analyses revealed significant positive shifts post-workshop which included explaining:- GEP tests (OR=2.98; 95% CI, 1.38 to 6.42; P=.001), recurrence RSs (OR=3.99; 95% CI, 1.72 to 9.25; P<.001), benefits of chemotherapy (OR= 3.99; 95% CI, 1.82 to 8.75; P<.001; and harms OR=2.31; 95% CI, 1.37 to 3.92; P<.001) using jargon free language (OR=5.29; 95% CI, 2.27 to 12.35; P<.001). Patient simulator assessments also showed significant improvements as did HCPs’ self-assessments and ratings of their self-confidence when discussing different GEP tests with diverse patient types (P<.001).

Conclusion: These short, intensive, interactive TARGET workshops significantly improved HCPs’ communication about GEP results in ways likely to promote more informed decision-making by patients about chemotherapy.

Item Type: Article
Additional Information: This is the final published version of the article (version of record). It first appeared online via Springer at https://doi.org/10.1007/s10549-019-05316-7 - please refer to any applicable terms of use of the publisher.
Uncontrolled Keywords: risk of recurrence, genomic test results, breast cancer, chemotherapy, communication
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine and Health Sciences > Primary Care Health Sciences
Depositing User: Symplectic
Date Deposited: 06 Jun 2019 16:42
Last Modified: 03 Oct 2019 10:01
URI: https://eprints.keele.ac.uk/id/eprint/6454

Actions (login required)

View Item
View Item